GlassScriptPhysician profile
Joseph Adragna
NPI 1851658876
$2,135.06
in general payments reported to CMS, 2019-2025
30 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $277 · 2021: $350 · 2022: $515 · 2023: $394 · 2024: $267 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $494.53 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Boston Scientific Corporation | $281.60 | 2022-2025 | Axonics |
| Astellas Pharma US INC | $223.48 | 2020-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $152.71 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $110.54 | 2019-2020 | |
| Allergan, INC. | $92.46 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $86.59 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $70.47 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $70.29 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $55.19 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.68 | 2022 | |
| Glaxosmithkline, LLC. | $44.16 | 2022-2023 | Trelegy Ellipta |
| Teleflex LLC | $43.96 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.41 | 2021-2023 | |
| Exact Sciences Corporation | $38.82 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.36 | 2022 | |
| Procept Biorobotics Corporation | $22.38 | 2023 | Aquabeam Robotic System |
| Medtronic Minimed, INC. | $21.52 | 2020 | |
| Xeris Pharmaceuticals, INC. | $21.36 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.60 | 2021 | |
| Urogen Pharma, INC. | $18.09 | 2024 | |
| Merck Sharp & Dohme LLC | $17.91 | 2021 | |
| Olympus America INC. | $16.41 | 2023 | Cysto-Nephro Videoscope |
| Ultragenyx Pharmaceutical INC. | $16.20 | 2021 | |
| Axonics, INC. | $16.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.56 | 2021 | |
| Sanofi Pasteur INC. | $14.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.78 | 2021 | |
| Pacira Therapeutics, INC. | $13.25 | 2019 | |
| Myriad Genetic Laboratories, INC. | $12.79 | 2023 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Adragna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.